



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: 05 August 2025

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai – 400051
Security Code: 540596	Symbol: ERIS

SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e., TUESDAY, AUGUST 05, 2025

Dear Sir/Madam,

Pursuant to Regulation 30 read with Regulation 51 (Part A and Part B of Schedule III) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“**SEBI Listing Regulations**”) we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., Tuesday, August 05, 2025, inter alia, duly approved and took on record the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025.

In this regard, the following documents are enclosed:

- A copy of the said financial results along with the limited review report pursuant to Regulation 33 and Regulation 52 of the SEBI Listing Regulations. The limited review reports are submitted with unmodified opinion(s) (free from any qualifications).
- Details as per Regulation 52(4) of SEBI Listing Regulations.

The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 01:00 P.M.

This is for your information and record.

Thanking You,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer
Membership No: A26493

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

Walker Chandiook & Co LLP

Walker Chandiook & Co LLP

Block No. D/15th Floor,
Cabin No. A8 to A10
"West Gate" Near YMCA Club,
S.G Highway, Sarkhej Road,
Ahmedabad-380015
Gujarat, India

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Eris Lifesciences Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Eris Lifesciences Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), and joint venture (refer Annexure 1 for the list of subsidiaries and joint venture included in the Statement) for the quarter ended 30 June 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune



Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker Chandiook & Co LLP

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the interim financial results of eight subsidiaries included in the Statement, whose financial information reflects total revenues of ₹ 656.69 Crores total net profit after tax of ₹ 137.68 Crores, total comprehensive income of ₹ 137.61 Crores, for the quarter ended on 30 June 2025, as considered in the Statement. The Statement also includes the Group's share of net loss after tax of ₹ 0.89 Crores and total comprehensive loss of ₹ 0.89 Crores, for the quarter ended on 30 June 2025, as considered in the Statement, in respect of one joint venture, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint venture is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.


6. The review of unaudited consolidated quarterly financial results for the period ended 30 June 2024 and audit of consolidated financial results for the quarter and year ended 31 March 2025 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP who have expressed unmodified conclusion vide their review report dated 2 August 2024 and unmodified opinion vide their audit report dated 19 May 2025, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement.

Our conclusion is not modified in respect of this matter.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013


Ashish Gupta

Partner

Membership No. 504662

UDIN: 25504662BMOOGZ2140



Place: New Delhi

Date: 5 August 2025

Walker Chandiook & Co LLP

Annexure 1 to the Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

List of entities included in the Statement

Holding Company

Sr. No.	Name of entity
1	Eris Lifesciences Limited

Subsidiaries

Sr. No.	Name of entities
1	Eris Therapeutics Limited
2	Aprica Healthcare Limited (Step-down subsidiary)
3	Eris Oaknet Healthcare Private Limited (Step-down subsidiary)
4	Eris Healthcare Private Limited
5	Eris M. J. Biopharm Private Limited
6	Eris Pharmaceuticals Limited
7	Eris Bionxt Private Limited (Formerly known as Chemman Labs Private Limited)
8	Swiss Parenterals Limited

Joint venture

Sr. No.	Name of entity
1	Levim Lifetech Private Limited





Statement of Unaudited Consolidated Financial results for the quarter ended June 30, 2025

		[Rs in Crore except per share data]			
Sr. No.	Particulars	For Quarter ended			For Year ended
		June 30, 2025 (Unaudited)	March 31, 2025 (Refer note 3)	June 30, 2024 (Unaudited) (Refer note 7)	March 31, 2025 (Audited)
1	Income				
	Revenue from Operations				
	Sale of products	771.56	702.60	715.59	2,879.26
	Other operating income	1.44	2.70	4.13	14.38
	Total Revenue from Operations	773.00	705.30	719.72	2,893.64
	Other Income	2.69	7.95	1.64	18.36
	Total Income	775.69	713.25	721.36	2,912.00
2	Expenses				
	Cost of materials consumed	70.10	68.28	66.47	276.34
	Purchase of stock-in-trade	104.26	95.98	125.57	473.12
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	10.28	5.99	(11.45)	(35.47)
	Employee benefits expense	144.43	121.45	132.62	505.09
	Finance Costs	48.68	54.28	60.37	231.29
	Depreciation and amortisation expense	70.51	77.25	75.74	315.46
	Other expenses	167.22	161.21	156.52	657.36
	Total Expenses	615.48	584.44	605.84	2,423.19
3	Profit before share of profit from investment in joint venture and tax for the period / year (1-2)	160.21	128.81	115.52	488.81
4	Share of (profit) from investment in joint venture, net of tax	(0.89)	(0.06)	-	(0.06)
5	Profit before tax for the period / year (3-4)	161.10	128.75	115.52	488.75
6	Tax Expense				
	Current Tax	56.31	31.39	25.34	111.84
	Deferred Tax	(20.31)	(4.87)	0.63	2.36
	Total Tax Expense	36.00	26.52	25.97	114.20
7	Net Profit for the period / year (5-6)	125.10	102.23	89.55	374.55
	Attributable to :				
	- Owners of the Company	117.99	93.84	83.31	351.84
	- Non controlling interest	7.11	8.51	6.24	22.83
8	Other Comprehensive loss				
	Items that will not be reclassified to profit or loss	(0.84)	(1.62)	(1.19)	(3.63)
	Income tax relating to items that will not be reclassified to profit or loss	0.27	(0.33)	0.40	0.34
	Other Comprehensive loss for the period / year	(0.57)	(1.95)	(0.79)	(3.29)
	Attributable to :				
	- Owners of the Company	(0.56)	(1.84)	(0.79)	(3.18)
	- Non controlling interest	(0.01)	(0.11)	0.00	(0.11)
9	Total Comprehensive Income				
	Attributable to :				
	- Owners of the Company	117.43	92.01	82.52	348.66
	- Non controlling interest	7.10	8.40	6.24	22.72
	Total Comprehensive Income for the period / year (7+8)	124.53	100.40	88.76	371.38
11	Paid Up Equity Share Capital (Face Value of Rs 1 each)	13.62	13.62	13.61	13.62
12	Other Equity				2,840.74
13	Earnings Per Share (of Rs 1 each) (not annualised) :				
	Basic	8.66	6.90	6.11	25.85
	Diluted	8.64	6.89	6.10	25.81



Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



Notes to Unaudited Consolidated Financial results

- 1 The above statement of Unaudited Consolidated Financial results ("the Statement") have been recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 05, 2025.
- 2 The Unaudited Consolidated Financial results of the Holding Company have been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards ('Ind AS') 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (as amended).
- 3 The figures for the quarter ended March 31, 2025 as reported in these financial results are the balancing figures between the Audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the previous financial year which was subject to limited review.
- 4 The Holding Company has issued and allotted 34,756 ordinary shares of Rs 1 each under the Company's Employee Stock Option Scheme 2021 during the quarter ended June 30, 2025. Consequently, the issued and paid-up Share Capital of the Company as on June 30, 2025 stands increased to Rs 13.62 crore.
- 5 The Holding Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
- 6 During the previous year ended March 31, 2025, the Holding Company has acquired 1,43,13,418 equity shares representing 100% of the equity share capital of Eris Bionxt Private Limited (formerly known as Chemman Labs Private Limited), from its erstwhile shareholders for a consideration of Rs. 27 Crores. The transaction achieved closure in October 2024, on completion of all relevant conditions precedent to the transaction. The Holding Company is in the process of making final determination of fair values of identified assets and liabilities for the purpose of Purchase price allocation. Pending this, the business combination has been accounted based on provisional fair valuation report. The results of the current quarter ended June 30, 2025 are not comparable with those of corresponding periods included in the aforesaid statement due to said acquisition.
- 7 During the year ended March 31, 2024, the Holding Company had acquired 51% stake in Swiss Parenterals Limited for a consideration (excluding acquisition expense) of Rs 637.50 crore. The Holding Company has completed the final determination of fair values of identified assets and liabilities for the purpose of Purchase Price Allocation for the aforesaid acquisitions in the previous year ended March 31, 2025. Consequent to above the Holding Company has restated the reported amounts of the previous periods as required by the applicable accounting standards.

The summarized position of the reported and restated amounts is as below:

(Rs in crore)

Particulars	Quarter ended June 30, 2024	
	Reported	Restated
Profit before tax	115.32	115.52
Profit after tax	89.42	89.55
Total Other Comprehensive Income	88.63	88.76



Place: Ahmedabad
Date: August 05, 2025



For Eris Lifesciences Limited,

Amit Bakshi
Chairman and Managing Director
DIN : 01250925

Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter ended June 30, 2025

Particulars	Quarter ended			Year ended
	June 30, 2025 (Unaudited)	March 31, 2025 (Unaudited)	June 30, 2024 (Unaudited) (Refer note 7)	March 31, 2025 (Audited)
Debt – Equity Ratio (in times) (Total Debt(including lease liabilities)/Total Equity)	0.74	0.76	0.95	0.76
Debt Service Coverage Ratio (in times) (Profit after tax-Other income+ Depreciation and amortisation expense+Finance Costs+Committed Principal repayments made during the period for long term loans/Finance Costs +Committed Principal repayments made during the period for long term loans)	2.60	2.36	2.21	2.24
Interest service coverage ratio (in times) (Earnings before Interest and Tax/Finance Costs)	4.29	3.37	2.91	3.11
Outstanding redeemable preference shares (quantity and value)	NA	NA	NA	NA
Capital redemption reserve/debenture redemption reserve (Rs in crore)	0.17	0.17	0.17	0.17
Net worth (Rs in crore)	3,399.10	3,271.76	3,078.22	3,271.76
Net profit after tax (Rs in crore)	125.10	102.35	89.55	374.67
Earnings per share				
Basic	8.66	6.90	6.11	25.85
Diluted	8.64	6.89	6.10	25.81
Current Ratio (in times) (Current Assets/Current Liabilities)	0.93	0.89	0.92	0.89
Long term debt to working capital (in times) (Long-term borrowing+Lease liabilities including its current maturity/Current Assets-Current liabilities (excluding current maturity))	8.77	14.74	9.07	14.74
Bad debts to Account receivable ratio (in times) (Bad debts/Trade receivables)	Nil	Nil	Nil	Nil
Current liability ratio (in times) (Current liabilities/Total liabilities)	0.38	0.37	0.35	0.37
Total debts to total assets (in times) (Total Debt (including lease liabilities)/Total Assets)	0.35	0.35	0.41	0.35
Debtors' turnover* (in times) (Sales/Trade receivables)	5.48	6.28	4.82	6.28
Inventory Turnover Ratio* (in times) (Cost of goods sold/Average Inventory)	2.41	2.73	2.57	2.73
Operating margin percent (Earnings before Interest and Tax/Revenue from Operations)	27.02%	25.96%	24.44%	24.89%
Net profit margin percent (Profit after tax/Revenue from Operations)	16.18%	14.51%	12.44%	12.95%

*Quarterly ratios based on trailing twelve months values.



Walker ChandioK & Co LLP

Block No. D/15th Floor,
Cabin No. A8 to A10
"West Gate" Near YMCA Club,
S.G Highway, Sarkhej Road,
Ahmedabad-380015
Gujarat, India

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Eris Lifesciences Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Eris Lifesciences Limited ('the Company') for the quarter ended 30 June 2025, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune



Walker ChandioK & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker Chandiook & Co LLP


52 read with Regulation 63 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The review of standalone unaudited quarterly financial results for the period ended 30 June 2024 and audit of standalone financial results for the quarter and year ended 31 March 2025 included in the Statement was carried out and reported by Deloitte Haskins & Sells LLP who has expressed unmodified conclusion vide their review report dated 2 August 2024 and unmodified opinion vide their audit report dated 19 May 2025, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013



Ashish Gupta

Partner

Membership No. 504662

UDIN: 25504662BMOOGY7760



Place: New Delhi

Date: 5 August 2025



Statement of Unaudited Standalone Financial results for the quarter ended June 30, 2025

		[Rs. in Crore except per share data]			
Sr. No.	Particulars	For Quarter ended			For Year ended
		June 30, 2025 (Unaudited)	March 31, 2025 (Refer note 3)	June 30, 2024 (Unaudited)	March 31, 2025 (Audited)
1	Income				
	Revenue from Operations				
	Sale of products	567.90	395.71	449.17	1,663.63
	Other operating income	10.74	9.06	7.52	34.12
	Total Revenue from Operations	578.64	404.77	456.69	1,697.75
	Other Income	22.68	16.75	5.16	35.51
	Total Income	601.32	421.52	461.85	1,733.26
2	Expenses				
	Cost of materials consumed	24.12	9.83	24.40	68.35
	Purchase of stock-in-trade	106.69	119.02	120.41	474.44
	Changes in inventories of finished goods, work-in- progress and stock-in-trade	50.71	(4.53)	(14.29)	(43.54)
	Employee benefits expense	93.78	81.41	103.75	361.92
	Finance Costs	45.14	53.16	56.17	220.24
	Depreciation and amortisation expense	37.60	43.38	45.55	181.77
	Other expenses	87.02	78.07	99.04	350.03
	Total Expenses	445.06	380.34	435.03	1,613.21
3	Profit before tax for the period / year (1-2)	156.26	41.18	26.82	120.05
4	Tax Expense				
	Current Tax	27.17	8.51	4.69	21.98
	Deferred Tax	29.10	2.20	5.09	20.68
	Total Tax Expense	56.27	10.71	9.78	42.66
5	Net Profit for the period / year (3-4)	99.99	30.47	17.04	77.39
6	Other Comprehensive loss				
	Items that will not be reclassified to loss	(0.77)	(1.18)	(1.10)	(3.10)
	Income tax relating to items that will not be reclassified to profit or (loss)	0.27	(0.41)	0.38	0.26
	Other Comprehensive loss for the period / year	(0.50)	(1.59)	(0.72)	(2.84)
7	Total Comprehensive Income for the period / year (5+6)	99.49	28.88	16.32	74.55
8	Paid Up Equity Share Capital (Face Value of Rs 1 each)	13.62	13.62	13.61	13.62
9	Other Equity				2,501.28
10	Earnings Per Share (of Rs 1 each) (not annualised) :				
	Basic	7.34	2.24	1.25	5.69
	Diluted	7.33	2.23	1.25	5.68



Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

Notes to Unaudited Standalone Financial results

- 1 The above statement of Unaudited Standalone Financial results ("the Statement") have been recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 05, 2025.
- 2 The Unaudited Standalone Financial results of the Company have been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards ('Ind AS') 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (as amended).
- 3 The figures for the quarter ended March 31, 2025 as reported in these financial results are the balancing figures between the Audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the previous financial year which was subject to limited review.
- 4 The Company has issued and allotted 34,756 ordinary shares of Rs 1 each under the Company's Employee Stock Option Scheme 2021 during the quarter ended June 30, 2025. Consequently, the issued and paid-up Share Capital of the Company as on June 30, 2025 stands increased to Rs 13.62 crore.
- 5 The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".



Place: Ahmedabad
Date: August 05, 2025



For Eris Lifesciences Limited,

A handwritten signature in blue ink, appearing to read "Amit Bakshi".

Amit Bakshi
Chairman and Managing Director
DIN : 01250925

Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter ended June 30, 2025

Particulars	Quarter ended			Year ended
	June 30, 2025 (Unaudited)	March 31, 2025 (Unaudited)	June 30, 2024 (Unaudited)	March 31, 2025 (Audited)
Debt – Equity Ratio (in times) (Total Debt(including lease liabilities)/Total Equity)	0.89	0.89	1.07	0.89
Debt Service Coverage Ratio (in times) (Profit after tax-Other income+ Depreciation and amortisation expense+Finance Costs+Committed Principal repayments made during the period for long term loans/Finance Costs +Committed Principal repayments made during the period for long term loans)	2.14	1.52	1.50	1.48
Interest service coverage ratio (in times) (Earnings before Interest and Tax/Finance Costs)	4.46	1.77	1.48	1.55
Outstanding redeemable preference shares (quantity and value)	NA	NA	NA	NA
Capital redemption reserve/debenture redemption reserve (Rs in crore)	0.17	0.17	0.17	0.17
Net worth (Rs in crore)	2,618.51	2,514.90	2,545.21	2,514.90
Net profit after tax (Rs in crore)	99.99	30.47	17.04	77.39
Earnings per share				
Basic	7.34	2.24	1.25	5.69
Diluted	7.33	2.23	1.25	5.68
Current Ratio (in times) (Current Assets/Current Liabilities)	0.81	0.63	0.73	0.63
Long term debt to working capital (in times) (Long-term borrowing+Lease liabilities including its current maturity/Current Assets-Current liabilities (excluding current maturity))	64.47	(14.23)	(34.41)	(14.23)
Bad debts to Account receivable ratio (in times) (Bad debts/ Trade receivables)	Nil	Nil	Nil	Nil
Current liability ratio (in times) (Current liabilities/Total liabilities)	0.39	0.37	0.38	0.37
Total debts to total assets (in times) (Total Debt (including lease liabilities)/Total Assets)	0.44	0.43	0.49	0.43
Debtors' turnover* (in times) (Sales/ Trade receivables)	3.74	7.04	5.46	7.04
Inventory Turnover Ratio* (in times) (Cost of goods sold/Average Inventory)	3.34	3.53	2.89	3.53
Operating margin percent (Earnings before Interest and Tax/Revenue from Operations)	34.81%	23.31%	18.17%	20.04%
Net profit margin percent (Profit after tax/Revenue from Operations)	17.28%	7.53%	3.73%	4.56%

*Quarterly ratios based on trailing twelve months values.

